Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Liponex
Ottawa, Ontario, Canadaliponex.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Liponex was a Canadian biopharmaceutical company focused on the development of proprietary lipid-based therapies for the treatment of cardiovascular disease. The company's lead product candidate, Liponexin, was a purified egg yolk phospholipid formulation designed to enhance reverse cholesterol transport and increase high-density lipoprotein (HDL) levels. By targeting the removal of cholesterol from the arterial wall, Liponex aimed to provide a novel approach to managing dyslipidemia and reducing the risk of atherosclerosis. Headquartered in Ottawa, the company was publicly traded on the Toronto Stock Exchange before being acquired by Aeterna Zentaris in 2008.
- Therapeutic areas
- Cardiovascular
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Liponex.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Liponex.